ArticleRadiation oncology (London, England)2025
Defining occult disease in glioblastoma using spectroscopic MRI: implications for clinical target volume delineation.
Article in Radiation oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Radiation Effects on Normal Brain in Subjects With Recurrent Glioblastoma by Spectroscopic MRI.NMR in biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundOutcomes in glioblastoma are improved by surgical resection and adjuvant radiation (RT). In primary GBM (pGBM), large clinical target volume (CTV) margins typically cover occult invasion. In recurrent GBM (rGBM), RT often uses tiny CTV margins that likely omit occult invasion due to re-RT radiation necrosis concerns. Whole-brain spectroscopic MRI (sMRI) is an emerging technique with similar resolution to PET that may help define the CTV for rGBM.
methodsPatients with pGBM (n = 18) and rGBM (n = 19) underwent sMRI with RT simulation. T1-post contrast (T1PC) and T2/FLAIR MRI volumes were contoured. sMRI generated choline/N-acetylaspartate > 2x (Cho/NAA > 2x) volumes are known to correlate with high-risk invasion. Hausdorff distances were calculated to define the margin necessary to cover Cho/NAA > 2x in pGBM and rGBM. In rGBM, mock CTV expansions from T1PC volumes were created to determine non-selective CTV expansion sizes needed to cover Cho/NAA > 2x volumes.
resultsFor pGBM, the median T1PC, Cho/NAA > 2x, and T2/FLAIR volumes were 32.3 cc, 45.0 cc, and 74.8 cc respectively. For rGBM, the median T1PC, Cho/NAA > 2x, and T2/FLAIR volumes were 21.7 cc, 58.9 cc, and 118.3 cc, respectively. T2/FLAIR volumes increased more relative to T1PC volumes in rGBM than pGBM (p ≤ 0.001). Meanwhile, the median Hausdorff distance between T1PC and Cho/NAA > 2x was 22.9 mm in pGBM and 25.7 mm in rGBM, suggesting that the high-risk volume does not significantly change. In rGBM, it is common to use no CTV expansion from the T1PC volume which only included 61% of high-risk Cho/NAA > 2x volume. Conversely, T1PC expansions of 10-, 15-, and 20-mm covered 87%, 94%, and 98% of Cho/NAA > 2x volume.
conclusionssMRI Cho/NAA > 2x delineates high-risk occult disease in glioblastoma and extends beyond T1PC MRI borders. Typical large CTV expansions in pGBM mostly include Cho/NAA > 2x volumes. However, small CTV expansions commonly used in rGBM poorly cover Cho/NAA > 2x, suggesting that larger CTV expansions or Cho/NAA > 2x guidance may be of benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.